UBR5 and neoplasm: Nevertheless, CRISPR/Cas9-mediated combined abrogation of UBR5 and PD-L1 expression offers synergistic therapeutic effects than each blockade alone, with a profound effect on the tumor microenvironment (Wu et al., 2022).